Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice.
Brobert G, García RL, Garbe E, Bezemer ID, Layton D, Friberg L, Suzart-Woischnik K, Alderson J, Winchester C, Herings RM, Jobski K, Schink T, Shakir S, Soriano-Gabarró M, Wallander MA. Brobert G, et al. Value Health. 2014 Nov;17(7):A473-4. doi: 10.1016/j.jval.2014.08.1350. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201360 Free article. No abstract available.
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.
García-Rodríguez LA, Wallander MA, Friberg L, Ruigomez A, Schink T, Bezemer I, Herings R, Shakir S, Evans A, Davies M, Suzart-Woischnik K, Vora P, Balabanova Y, Soriano-Gabarró M, Brobert G. García-Rodríguez LA, et al. Among authors: brobert g. Expert Opin Drug Saf. 2020 Nov;19(11):1513-1520. doi: 10.1080/14740338.2020.1798928. Epub 2020 Aug 4. Expert Opin Drug Saf. 2020. PMID: 32700977
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries.
García Rodríguez LA, Ruigómez A, Schink T, Voss A, Smits E, Swart KMA, Balabanova Y, Suzart-Woischnik K, Brobert G, Herings RMC. García Rodríguez LA, et al. Among authors: brobert g. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):493-500. doi: 10.1080/14740338.2023.2181334. Epub 2023 Feb 22. Expert Opin Drug Saf. 2023. PMID: 36795067
45 results